Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study

Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study

Introduction: Targeting the alternative complement pathway (AP) is an attractive therapeutic strategy because of its role in immunoglobulin A nephropathy (IgAN) pathophysiology. Iptacopan (LNP023), a proximal complement inhibitor that specifically binds to factor B and inhibits the AP, reduced prote...

Full description

Bibliographic Details
Main Authors: Dana V. Rizk, Brad H. Rovin, Hong Zhang, Naoki Kashihara, Bart Maes, Hernán Trimarchi, Vlado Perkovic, Matthias Meier, Dmitrij Kollins, Olympia Papachristofi, Alan Charney, Jonathan Barratt
Format: Article
Language:English
Published: Elsevier 2023-05-01
Series:Kidney International Reports
Subjects:
alternative complement pathway
eGFR slope
Factor B
IgAN
iptacopan (LNP023)
proteinuria
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024923000505

Internet

http://www.sciencedirect.com/science/article/pii/S2468024923000505

Similar Items